422 related articles for article (PubMed ID: 33513373)
21. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Garcia-Manero G; Fenaux P; Al-Kali A; Baer MR; Sekeres MA; Roboz GJ; Gaidano G; Scott BL; Greenberg P; Platzbecker U; Steensma DP; Kambhampati S; Kreuzer KA; Godley LA; Atallah E; Collins R; Kantarjian H; Jabbour E; Wilhelm FE; Azarnia N; Silverman LR;
Lancet Oncol; 2016 Apr; 17(4):496-508. PubMed ID: 26968357
[TBL] [Abstract][Full Text] [Related]
22. Activity of azacitidine in chronic myelomonocytic leukemia.
Costa R; Abdulhaq H; Haq B; Shadduck RK; Latsko J; Zenati M; Atem FD; Rossetti JM; Sahovic EA; Lister J
Cancer; 2011 Jun; 117(12):2690-6. PubMed ID: 21656746
[TBL] [Abstract][Full Text] [Related]
23. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
Kantarjian HM; Roboz GJ; Kropf PL; Yee KWL; O'Connell CL; Tibes R; Walsh KJ; Podoltsev NA; Griffiths EA; Jabbour E; Garcia-Manero G; Rizzieri D; Stock W; Savona MR; Rosenblat TL; Berdeja JG; Ravandi F; Rock EP; Hao Y; Azab M; Issa JJ
Lancet Oncol; 2017 Oct; 18(10):1317-1326. PubMed ID: 28844816
[TBL] [Abstract][Full Text] [Related]
24. [Clinical Characteristics and Survival Analysis of Patients with Chronic Myelomonocytic Leukemia].
Wang JY; Chen JF; Wang SF; Guo QH; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):476-482. PubMed ID: 37096522
[TBL] [Abstract][Full Text] [Related]
25. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
Aribi A; Borthakur G; Ravandi F; Shan J; Davisson J; Cortes J; Kantarjian H
Cancer; 2007 Feb; 109(4):713-7. PubMed ID: 17219444
[TBL] [Abstract][Full Text] [Related]
26. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
[TBL] [Abstract][Full Text] [Related]
27. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Beran M; Estey E; O'Brien SM; Giles FJ; Koller CA; Kornblau S; Keating M; Kantarjian HM
Leuk Lymphoma; 1998 Nov; 31(5-6):521-31. PubMed ID: 9922042
[TBL] [Abstract][Full Text] [Related]
28. Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).
Kenealy M; Patton N; Filshie R; Nicol A; Ho SJ; Hertzberg M; Mills T; Prosser I; Link E; Cowan L; Zannino D; Seymour JF
Leuk Lymphoma; 2017 Feb; 58(2):298-307. PubMed ID: 27268068
[TBL] [Abstract][Full Text] [Related]
29. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
[TBL] [Abstract][Full Text] [Related]
30. PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia.
Chamseddine AN; Cabrero M; Wei Y; Ganan-Gomez I; Colla S; Takahashi K; Yang H; Bohannan ZS; Garcia-Manero G
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S67-73. PubMed ID: 27521329
[TBL] [Abstract][Full Text] [Related]
31. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine.
Adès L; Sekeres MA; Wolfromm A; Teichman ML; Tiu RV; Itzykson R; Maciejewski JP; Dreyfus F; List AF; Fenaux P; Komrokji RS
Leuk Res; 2013 Jun; 37(6):609-13. PubMed ID: 23415110
[TBL] [Abstract][Full Text] [Related]
32. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
Taylor J; Mi X; Penson AV; Paffenholz SV; Alvarez K; Sigler A; Chung SS; Rampal RK; Park JH; Stein EM; Tallman MS; Sen F; Gönen M; Abdel-Wahab O; Klimek VM
Lancet Haematol; 2020 Aug; 7(8):e566-e574. PubMed ID: 32735836
[TBL] [Abstract][Full Text] [Related]
33. Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival.
Pleyer L; Germing U; Sperr WR; Linkesch W; Burgstaller S; Stauder R; Girschikofsky M; Schreder M; Pfeilstocker M; Lang A; Sliwa T; Geissler D; Schlick K; Placher-Sorko G; Theiler G; Thaler J; Mitrovic M; Neureiter D; Valent P; Greil R
Leuk Res; 2014 Apr; 38(4):475-83. PubMed ID: 24522248
[TBL] [Abstract][Full Text] [Related]
34. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
35. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Bazinet A; Darbaniyan F; Kadia TM; Venugopal S; Kanagal-Shamanna R; DiNardo CD; Borthakur G; Jabbour EJ; Daver NG; Pemmaraju N; Konopleva MY; Ravandi F; Sasaki K; Chien KS; Hammond D; Pierce SA; Kantarjian HM; Garcia-Manero G; Montalban-Bravo G
Cancer; 2023 Feb; 129(4):560-568. PubMed ID: 36458426
[TBL] [Abstract][Full Text] [Related]
36. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.
Braun T; Itzykson R; Renneville A; de Renzis B; Dreyfus F; Laribi K; Bouabdallah K; Vey N; Toma A; Recher C; Royer B; Joly B; Vekhoff A; Lafon I; Sanhes L; Meurice G; Oréar C; Preudhomme C; Gardin C; Ades L; Fontenay M; Fenaux P; Droin N; Solary E;
Blood; 2011 Oct; 118(14):3824-31. PubMed ID: 21828134
[TBL] [Abstract][Full Text] [Related]
37. Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.
Moreno Berggren D; Kjellander M; Backlund E; Engvall M; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ungerstedt J; Ejerblad E
Br J Haematol; 2021 Feb; 192(3):474-483. PubMed ID: 32501529
[TBL] [Abstract][Full Text] [Related]
38. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.
Parikh SA; Tefferi A
Am J Hematol; 2013 Nov; 88(11):967-74. PubMed ID: 23963888
[TBL] [Abstract][Full Text] [Related]
39. Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.
Duchmann M; Braun T; Micol JB; Platzbecker U; Park S; Pilorge S; Beyne-Rauzy O; Vey N; Sébert M; Gruson B; Dumas PY; Guieze R; Chretien ML; Laribi K; Chait Y; Legros L; Sahnes L; Hirsch P; Salanoubat C; Solary E; Fenaux P; Itzykson R
Blood Cancer J; 2017 May; 7(5):e562. PubMed ID: 28498370
[No Abstract] [Full Text] [Related]
40. Treatment options and survival in real life during the past three decades in patients with chronic myelomonocytic leukemia.
Reiser J; Geissler K
Wien Med Wochenschr; 2023 Feb; 173(1-2):34-40. PubMed ID: 36282401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]